Genmab Appoints Dr. Katja Nielsen as General Manager for Germany – Strategic Expansion of European Presence

Genmab A/S (Nasdaq: GMAB) has announced the appointment of Dr. Katja Nielsen as General Manager for Germany. The international biotechnology company headquartered in Copenhagen is strengthening its commercial presence in Europe to bring its innovative antibody-based medicines to new markets.

With over 20 years of leadership experience in the pharmaceutical industry, Dr. Nielsen brings deep expertise in oncology, product launches, market access, and building high-performing teams. Her previous leadership roles at Gilead, Daiichi-Sankyo, and Eli Lilly highlight her strategic ability to navigate complex markets.

Dr. Nielsen will assume her new role on August 1. As General Manager, she will be responsible for building and leading Genmab’s operations in Germany, driving growth, and preparing for future product launches.

“Katja’s appointment is a major step in our European expansion,” said Brad Bailey, Executive Vice President and Chief Commercial Officer at Genmab. “Her broad expertise and experience make her ideally suited to lead our business in one of Europe’s largest healthcare markets.”

Dr. Nielsen also shared her excitement: “I’m proud to be joining a company that’s known for scientific innovation and its commitment to improving the lives of people with cancer. Germany offers unique opportunities and challenges – and as an avid mountaineer, I’m used to adapting to individual challenges and exploring new ones. I look forward to helping Genmab build and scale a leading presence in Europe.”

Founded in 1999 in Denmark, Genmab specializes in antibody-based therapeutics. The company’s vision is to transform the lives of people with cancer and other serious diseases by 2030 through knock-your-socks-off (KYSO®) antibody medicines.